Login to Your Account



Enobia Adds $40M for Hypophosphatasia ERT

By Jennifer Boggs


Thursday, August 11, 2011
Montreal-based Enobia Pharma Inc. padded its coffers via a $40 million private placement to support ongoing work on ENB-0040, an enzyme replacement therapy for rare genetic bone disorder hypophosphatasia (HPP).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription